Figure 2
Figure 2. Expansion of EBV-specific effector T cells in PTLD. Polyclonal EBNA1-specific T cells and polyclonal BZLF1-specific T cells were generated from 19 healthy control and 14 EBV+ PTLD PBMCs using the 14-day peptide pool expansion protocol. On day 14, the cells were restimulated with the appropriate peptide pool and assayed for IFN-γ and CD107a/b production using flow cytometry. Results are as follows: (A) Number of IFN-γ or CD107a/b-producing CD8+ T cells expanded from 106 PBMCs. (B) Number of IFN-γ–producing CD4+ T cells (represented by the CD8− CD3+ population). (C) Comparison of EBNA1 and BZLF1-specific IFN-γ–producing CD8+ and CD4+ T cells

Expansion of EBV-specific effector T cells in PTLD. Polyclonal EBNA1-specific T cells and polyclonal BZLF1-specific T cells were generated from 19 healthy control and 14 EBV+ PTLD PBMCs using the 14-day peptide pool expansion protocol. On day 14, the cells were restimulated with the appropriate peptide pool and assayed for IFN-γ and CD107a/b production using flow cytometry. Results are as follows: (A) Number of IFN-γ or CD107a/b-producing CD8+ T cells expanded from 106 PBMCs. (B) Number of IFN-γ–producing CD4+ T cells (represented by the CD8 CD3+ population). (C) Comparison of EBNA1 and BZLF1-specific IFN-γ–producing CD8+ and CD4+ T cells

Close Modal

or Create an Account

Close Modal
Close Modal